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It is well known that in mice the extension in lifespan by rapamycin is sexually dimorphic, in that it has a larger
effect in females than males. In a previous study we showed that in male C57BL6 mice, rapamycin had less
profound effects in both gene expression and liver metabolites when compared to dietary restriction (DR), but no
data was available in females. Because recent studies showed that rapamycin increases longevity in a dose
dependent manner and at every dose tested the effect remains larger in females than in males, we hypothesized
that rapamycin should have a stronger effect on gene expression in females, and this effect could be dose
dependent. To test this hypothesis, we measured the changes in liver gene expression induced by rapamycin
(14 ppm) with a focus on several genes involved in pathways known to play a role in aging and that are altered by
DR. To investigate whether any effects are dose dependent, we also analyzed females treated with two additional
doses of rapamycin (22 and 42 ppm). We observed striking differences between male and female in gene
expression at 14 ppm, where females have a larger response to rapamycin than males, and the effects of rapamycin
in females resemble what we observed under DR. However, these effects were generally not dose dependent.
These data support the notion that female mice respond better to rapamycin, and at least with the set of genes
studied here, the effect of rapamycin in females resemble the effect of DR.
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Several studies published in the last few years indicate
that rapamycin extends lifespan in different species, in-
cluding the study by the NIA Intervention Testing Pro-
gram (ITP), which reported that rapamycin increases
lifespan in mice when the treatment started at either 9
or 20 months (Harrison et al. 2009), and the result is
dose-dependent (Miller et al. 2014). Rapamycin is a clin-
ically approved drug known to inhibit the mammalian
Target of Rapamycin (mTOR), a serine/threonine kinase
that regulates the response of eukaryotic cells to nutri-
ents, growth factors, and cellular energy status. Interest-
ingly, it has been reported that when used acutely, the
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in any medium, provided the original work is p1 (TORC1), but chronic exposure to the drug results in
additional inhibition of TORC2 (Lamming et al. 2012).
Based on studies in invertebrates using TOR and other
mutants downstream in the pathway, as well as mice
with deletion of the mTOR-regulated S6 kinase 1
(S6K1), it has been suggested that rapamycin acts as a
dietary restriction mimetic (Selman et al. 2009). Further-
more, when treatment was initiated at 9 months of age,
the ITP investigators reported that rapamycin decreased
the age-related gain in body weight, again suggesting
that the effects could be similar to those of DR. In
mouse, rapamycin also has significant positive effects on
healthspan, preventing the onset of many age-related
diseases including Alzheimer’s, Parkinson’s, several types
of natural and experimentally induced cancer, athero-
sclerosis, ventricular hypertrophy and others. At the
physiopathological level, rapamycin has positive effects
on age-related alterations in heart, liver, adrenal glands,
endometrium, and tendon, as well as the age-dependentpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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are similar to those observed in mice under dietary re-
striction (DR). Rapamycin also has negative effects on
the development of cataracts, as well as testicular atro-
phy and defects in glucose handling reminiscent of those
observed in diabetes (Wilkinson et al. 2012).
In spite of these similarities at the physiological level,
our previous data using gene arrays and metabolomics
in male mice treated with rapamycin for 6 months
showed that although 40% dietary restriction and 14
ppm rapamycin have a similar inhibitory effect on
mTOR signaling, they have quite different effects on
gene expression and metabolites, suggesting significant
differences between dietary restriction and rapamycin at
the molecular level (Fok et al. 2013, 2014a).
Several studies have shown that the life extension in-
duced by rapamycin is sexually dimorphic, in that even
though the effect is significant in mice of both sexes, life-
span extension is consistently larger in female than in male
mice. For example the most recent study from the ITP
showed that the lowest dose of rapamycin used (4.2 ppm)
increased median longevity by 16% vs. 3% for females and
males respectively. A similar dimorphism was observed at
both the middle (14 ppm; 21% vs. 13%) and the highest
dose (42 ppm; 26% vs. 23%) (Miller et al. 2014).
Taking in consideration these gender differences, in
this work we compared male and female mice with re-
spect to the expression of several genes involved in path-
ways that are known to play a role in longevity, and to
be affected (based on our microarray data) by DR. The
pathways we chose include: sirtuins, Foxo, circadian
rhythm genes, degradation pathways (Ub-proteasome
and autophagy), and the unfolding protein response. As
in previous work (Fok et al. 2013; Fok et al. 2014a), we
focused on the liver, but based on recent data from the
ITP, we included female mice treated with three different
doses of rapamycin (14 ppm, 22 ppm and 42 ppm) for 6
months starting at 5 months of age, and compared the
results to female mice under DR (40%) for a similar
length of time and at the same ages. Our data show that
in females, effects of rapamycin on the expression of
these genes closely resemble the effect of DR. In con-
trast, rapamycin at 14 ppm did not have any effect on
the expression of these longevity-related genes in males.
We did not examine males at the higher doses of rapa-
mycin. These data may explain in part why females dis-
play a larger extension of lifespan than males in
response to rapamycin treatment.
Materials and methods
Animals and feeding regiment
C57BL/6 mice were purchased from The Jackson Labs (Bar
Harbor, ME) and placed on a commercial mouse chow,
7012 Teklad LM-450 (Harlan Laboratories, Madison, WI).At 5 months of age, the mice were separated into three
dietary regimens: ad libitium (AL), 40% diet restriction
(DR), and AL diet plus rapamycin in the food. The AL
group was fed a commercial mouse chow, Purina Mills
Test Diet Control #1810306 (Purina Mills, St. Louis,
MO). The DR group was fed 40% less food than eaten
by the AL mice. The male and female rapamycin group
was fed the AL diet supplemented with 14 ppm of en-
capsulated rapamycin in the food as described Harrison
et al. (2009). Mice were maintained on these dietary
conditions until 11 months of age (6 months of treat-
ment). For the female mice, there were two more groups
of mice fed with 22 and 42 ppm of rapamycin, respect-
ively. Mice were then euthanized (in the morning) by
carbon dioxide and liver and subcutaneous adipose tis-
sues were collected, snap frozen in liquid nitrogen, and
stored at −80°C until used. All procedures followed the
guidelines approved by the Institutional Animal Care
and Use Committee at the University of Texas Health
Science Center at San Antonio. (Kennedy et al. 2014).
RNA processing
Total RNA from frozen liver (25 mg) or subcutaneous
fat (100 mg) was extracted using RNeasy kit (Qiagen,
Valencia, CA) following manufacturer’s protocols. RNA
quality was assessed by Agilent Bioanalyzer (Agilent
Technologies, Santa Clara, CA), and RNA quantity was
determined using the Nanodrop (Thermo Scientific,
Wilmington, DE). 1 μg of total RNA was then processed
into cDNA by SuperScript® III First-Strand Synthesis
System for RT-PCR (Life Technologies, Grand Island, NY)
following manufacturer’s protocols. Primers were either
obtained from RealTimePrimers.com (Elkins Park, PA),
PrimerBank (http://pga.mgh.harvard.edu/primerbank, Wang
and Seed, 2003) or designed using OligoPerfect™ Primer
(Life Technologies, Grand Island, NY) and Primer-BLAST
(NCBI). The primer pairs used are described in Additional
file 1: Table S1. Quantitative real-time RT-PCR (qRT-
PCR) was performed using SYBR Green PCR Master Mix
(Life Technologies, Grand Island, NY) with detection by a
StepOnePlus™ Real-Time PCR System (Applied Biosystem,
Inc., Foster City, CA). Actin was used as a housekeeping
control. The qRT-PCR results were analyzed using ΔΔ CT
method. Data were expressed as relative fold change com-
pared to ad libitum (AL).
The genes studied in this work were: Forkhead box
protein O1(Foxo1), Sirtuin 1 (Sirt1), Sirtuin 3 (Sirt3),
circadian locomotor output cycles kaput (Clock), cryp-
tochrome 2(cry2), period homolog 1(per1), period
homolog 2 (per2), aryl hydrocarbon receptor nuclear
translocator-like (Arntl, or Bmal), Ubiquitin carboxyl-
terminal hydrolase 2 (Usp2), 26S proteasome non-ATPase
regulatory subunit 9 (psmd9), Microtubule-associated pro-
tein 1A/1B-light chain (LC3), Beclin 1, Lysosome-associated
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9 (Hspa9); protein disulfide isomerase family A, member 4
(Pdia4); 78 kDa glucose-regulated protein (Grp78) and
calreticulin (Calr).
Immunoblotting
Frozen liver tissue was homogenized with in ice-cold RIPA
buffer (50 mM Tris–HCl, pH7.4, 1% Nonidet P-40, 1%
Sodium deoxycholate, 0.15 M NaCl) supplemented with
protease and phosphatase inhibitors (Roche, Indianapolis,
IN) on ice. The supernatant was collected after centrifuga-
tion at 4°C, 12,000×g for 10 minutes. Proteins were sepa-
rated by sodium dodecyl sulfate–polyacrylamide gel
followed by transfer to PVDF membranes. Target proteins
were detected with the following specific monoclonal or
polyclonal antibodies: Actin (MP Biomedicals, Solon,
OH); Bmal1 (Abcam, Cambridge, MA); Psmd9 (Sigma,
St. Louis, MO). Grp78, Pdi, Sirt3 and LC3 from Cell
signaling (Danvers, MA). Actin was quantified as a
loading control. Images were analyzed by Imagelab soft-
ware (Bio-rad, Hercules, CA). Data were expressed as
means ± standard error of the mean (SEM).
Statistical analysis
All data were expressed as mean ± standard error of the
mean (SEM) of N = 6 to 8 samples per group, and were
analyzed by analysis of variance followed by Fisher’s pro-
tected least-significant procedure. A p-value of less than
0.05 (two-tail) was considered significant.
Results
In an effort to test the molecular basis for why the effect




























Figure 1 Rapamycin increases expression of Foxo and Sirtuin genes in fem
rapamycin (Rapa) on the expression of Foxo and Sirtuin genes was measur
AL; solid bars: DR; Gray bars: Rapa 14 ppm. The data were obtained from 6
asterisk denotes values that are significantly different (p ≤ 0.05) from AL mimales, we compared gene expression patterns in re-
sponse to rapamycin (14 ppm, the initial dose shown to
increase longevity in both male and female mice) in the
liver of male and female mice, using as reference animals
treated with DR (40%). Since a recent report by Miller
et al., 2014 showed that the effect of rapamycin on lon-
gevity is dose dependent and the effect is still larger in
females at all doses tested, changes in gene expression in
females using the doses of 22 and 42 ppm were also
evaluated. Our data showed that in female mice, rapa-
mycin significantly upregulates the expression of Foxo-1,
sirtuin-1 and 3 genes (Figure 1A), as observed for mice
from either sex under DR. In fact, at 14 ppm rapamycin
increased Sirt1 gene expression more than DR. In con-
trast, male animals at that dose of rapamycin failed to
increase expression of either of these genes (Figure 1B).
We did not observe a dose-dependent effect in gene ex-
pression when female animals were fed with higher
doses of rapamycin (22 or 42 ppm, Additional file 1:
Figure S1A). In fact, the effect was more muted at higher
doses of the drug.
It is well established that circadian rhythm genes are
altered by DR (Challet et al. 1998; Froy and Miskin
2007), which was also confirmed in this work, where the
expression of genes involved in the circadian rhythm
pathway (Figure 2), were significantly altered by DR in
both males and females, including downregulation of the
genes coding for Clock and Bmal, and overexpression of
Cry, Per1 and Per2, all of which are consistent with pre-
vious reports (Huang et al. 2011). With the exception of
clock downregulation, qualitatively similar results were
observed for expression of these genes in female mice
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ales but not in males. The effect of dietary restriction (DR) and
ed in liver samples from female (A) and male (B) mice. Open bars:
male and 8 female mice per group and expressed as mean ± SEM. An
ce.
Figure 2 In female but not male mice, rapamycin and dietary restriction alter the expression of circadian rhythm genes similarly. The effect of
dietary restriction (DR) and rapamycin (Rapa) on the expression of circadian rhythm genes was measured in liver samples from female (A) and
male (B) mice. Open bars: AL; solid bars: DR; Gray bars: Rapa 14 ppm. The data were obtained from 6 male and 8 female mice per group and
expressed as mean ± SEM. An asterisk denotes those values that are significantly different (p ≤ 0.05) from AL mice.
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ences in the expression of any of these genes when com-
pared to mice fed ad libitum (AL; Figure 2B), and no
dose dependent-effect in any of these genes was ob-
served in females (Additional file 1: Figure S1B).
Similar results were found when we measured the
gene transcripts for key proteins involved in degrad-
ation processes i.e., ubiquitin-proteasome and autoph-
agy pathways. For the ubiquitin-proteasome pathway,
we measured mRNA levels for Usp2 (ubiquitin specific
peptidase 2), a cysteine protease that cleaves ubiquitin
from the poly ubiquitin chains of proteins (RenatusFigure 3 Rapamycin changed the expression of gene related to proteolyti
restriction (DR) and Rapamycin (Rapa), on the expression of genes related t
was measured in liver samples of male (B and D) and female (A and C) m
and expressed as mean ± SEM. An asterisk denotes those values that are sig
DR; Gray bars: Rapa 14 ppm.et al., 2006; Stevenson et al. 2007) and Psmd9, a non-
ATPase subunit of the 19S regulatory complex which
aids in proteasome assembly and interacts with poly-
ubiquitin chains of target proteins, influencing ubiqui-
tination (Sangith et al., 2014). As shown in Figure 3A
and B, DR in both genders significantly upregulates
expression of both Usp2 and Psmd9 genes when
compared to AL mice, an effect that is mimicked in
females but not in males fed rapamycin. As before,
the maximum effect on the expression of these genes
was observed with rapamycin treatment at 14 ppm
(Figure 3C).c pathways like dietary restriction only in female. The effect of dietary
o ubiquitin-proteasome (A and B) and autophagy (C and D) pathways
ice. The data were obtained from 6 male and 8 female mice per group
nificantly different (p≤ 0.05) from AL mice. Open bars: AL; solid bars:
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LC3 genes, which code for proteins involved in the for-
mation of double membrane autophagosomes, which are
essential for macroautophagy. Again, expression of these
genes was induced by DR in animals of both sexes, and
by rapamycin only in females (Figure 3C and D). Rapa-
mycin had no effect on the expression of these genes in
males, and the effect in females was not dose-dependent
(Additional file 1: Figure S1C and D). Since females
showed an increase in the expression of these two
macroautophagy genes, we also analyzed expression of
the Lamp2 gene, which codes for a lysosomal membrane
protein involved in chaperone mediated autophagy. We
found that both DR and rapamycin treatment had a
similar effect in Lamp2 expression in females, where both
treatments increased its expression similarly (Additional
file 1: Figure S2A).
Finally, we investigated the effect of rapamycin on the
expression of selected genes involved in response to ER
stress pathways, including the unfolded protein response
(UPR) (Figure 4). For this pathway we measured the ex-
pression of Grp78, an ER chaperone (Li and Lee, 2006),
Hspa9, a heat-shock cognate protein that plays an import-
ant role in the ER stress response, Pdia4, a folding enzyme
localized in the ER lumen that also has chaperone activity
to prevent protein aggregation (Thomas et al., 2010)
and Calreticulin (Calr), a calcium binding chaperone
protein in the ER lumen involved in folding of newly
synthesized proteins (Saito et al., 1999). Figure 4A
shows that in females neither DR nor Rapa (14 ppm)
affected the levels of Grp78 mRNA, but they both
increased Hspa9 and Calr gene expression. However,
and contrary to DR, rapamycin had no effect on expres-
sion of the Pdia4 gene.
In males (Figure 4B), DR produced a significant in-
crease in the expression of Hspa9, and a non-significant
decrease in the expression of Grp78 and Pdia4. Rapamy-
cin (14 ppm) did not have a significant effect on any ofFigure 4 Rapamycin changes significantly the expression of genes involve
restriction (DR) and rapamycin (Rapa) on the expression of genes involved
(A) and male (B) mice. The data were obtained from 6 male and 8 female
those values that are significantly different (p ≤ 0.05) from AL mice. Open bthese mRNAs in male mice when compared to AL
controls.
In females, expression of Pdia4, Grp78 and Calr was
maximal at a higher dose of rapamycin (22 ppm), and
decreased at the highest dose (42 ppm). In contrast, ex-
pression of Hspa9, which is affected by 14 ppm, was not
induced at the higher doses of rapamycin (22 and
42 ppm; Additional file 1: Figure S2B).
To identify whether these changes in gene expression
are reflected in changes at the protein level, we used
western blot analysis to assess the levels of representa-
tive proteins from each pathway (Figure 5). Our data
show that in general there is a good correlation between
changes in gene expression and protein levels under DR
treatment. However, while we observed a similar trend
for most of the proteins studied, the correlation between
gene expression and protein levels under rapamycin
treatment was weaker, and only one protein (LC3)
showed statistically significant differences from control
AL female mice. No dose effect of rapamycin was ob-
served (Additional file 1: Figure S3).
To determine whether the changes in gene expression
observed in liver represent a systemic effect of rapamy-
cin in female mice, we used subcutaneous fat to measure
the expression of those genes that showed the most sig-
nificant changes in the liver. In Figure 6, we show that
DR and rapamycin (14 ppm) affected the expression of
most of the genes in a similar direction in subcutaneous
fat, but the effect of rapamycin is significantly different
from control group in only 3 genes of the 9 studied.
Once again, we did not observe a rapamycin dose-effect
in fat tissue (Additional file 1: Figure S4).
Discussion
Several studies have indicated that the effect of rapamy-
cin on longevity in mice is stronger in females than males.
This includes studies in UM-HET-3 mice (Harrison et al.
2009; Miller et al. 2014), as well as our own studies ind in the ER stress pathway only in females. The effect of dietary
in the ER stress pathway was measured in liver samples from female
mice per group and expressed as mean ± SEM. An asterisk denotes
ars: AL; solid bars: DR; Gray bars: Rapa 14 ppm.
Figure 5 Effect of dietary restriction (DR) and rapamycin on protein levels in the liver. The effect of dietary restriction (DR) and rapamycin (Rapa)
on protein levels was measured by Western blot analysis in livers obtained from 8 female mice per group and expressed as mean ± SEM. An
asterisk denotes those values that are significantly different (p ≤ 0.05) from AL mice. Open bars: AL; Solid bars: DR; Gray bars: Rapa 14 ppm.
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months (14 ppm) resulted in an increase in longevity of
11% for male and 16% for female C57BL/6 mice. Recently,
a study by Zhang et al. (2014) showed that if rapamycin is
started at 19 months of age, then only female C57BL/6
mice display an increase in lifespan (6%), while the treat-
ment had no effect on longevity in male mice. More re-
cently, Miller et al. showed that the extension of lifespan
by rapamycin in UM-HET3 mice is dose dependent, and
once again, the effect is larger in females than males at
every dose tested (for 42 ppm, they found a significant in-
crease of 26 and 23% respectively) (Miller et al. 2014).
Thus it is clear from the literature that the effect of rapa-
mycin on lifespan is sexually dimorphic.
In an effort to elucidate whether rapamycin and DR
extend lifespan through similar mechanisms, in a previ-
ous study we used microarray and metabolomic analysis
and showed that although treatment of male mice withFigure 6 Rapamycin and DR exert similar effects on gene expression in su
and rapamycin (Rapa) on gene expression was measured in subcutaneous fat
and an asterisk denotes those values that are significantly different (p ≤
14 ppm.either rapamycin (14 ppm) or DR (40%) for 6 months
produces an overlapping set of changes in gene expres-
sion in the liver, rapamycin effects were generally weaker
and it often showed no significant differences when
compared to AL. Furthermore, there were no significant
effects of rapamycin on a variety of liver metabolites
measured, which was not the case for DR. These data
were limited to only one gender, males, and since rapa-
mycin has a larger longevity effect on females than in
males, in this study we extended our observations to fe-
male mice and measured the effect of DR and rapamycin
on the expression of several genes involved in pathways
that are known to play a role in longevity. Generally, our
data show that in females rapamycin had effects that are
similar to those elicited by DR. For example, both inter-
ventions increased the expression of the transcription
factor FoxO-1 as well sirtuins-1 and 3, which suggests
that both DR and rapamycin may have a similar effectbcutaneous fat from female mice. The effect of dietary restriction (DR)
from 6 female mice per group. The data was expressed as mean ± SEM,
0.05) from AL mice. Open bars: AL; Solid bars: DR; Gray bars: Rapa
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important roles in regulating glucose metabolism and
cell death among other functions, and are known to play
a key role in determining longevity (Puigserver et al.
2003; Boily et al. 2008; Hallows et al. 2011; Lopez-Otin
et al. 2013). This possible effect on cell metabolism ap-
pears to be also corroborated by the similar effects of
both rapamycin and DR on the expression of genes re-
lated to the circadian rhythm pathway, which is believed
to play a role in healthspan (Wilkinson et al. 2012; Tevy
et al. 2013), thus controlling the expression of several hor-
mones that regulate metabolism and energy utilization.
For example, clock genes are involved in regulating glu-
cose metabolism in the liver (Rudic et al. 2004; Lamia
et al. 2008; Zhang et al. 2010), and are essential for the
maintenance of normal mitochondrial biogenesis and re-
spiratory function in skeletal muscle (Andrews et al.
2010). Thus an up-regulation of circadian rhythm path-
ways would be consistent with increased longevity and im-
proved healthspan, as observed in mice under DR and
females fed rapamycin.
Our data also suggest that in females, both DR and
rapamycin have a similar effect enhancing expression of
genes involved in the ubiquitin-proteasome, autophagy,
and UPR pathways. These pathways form part of the
proteostasis network, which is generally believed to be
one of the hallmarks of aging (Lopez-Otin et al. 2013;
Burch et al. 2014; Kennedy et al. 2014; Morimoto and
Cuervo 2014). Therefore, these data suggest that in fe-
males, both rapamycin and DR have a positive effect in
regulating the protein quality control machinery, and
also suggest that rapamycin may regulate stress resist-
ance mechanisms, by inducing the expression of genes
involved in the unfolding protein ER response, thus
helping to take care of the proper folding of newly syn-
thesized proteins.
Interestingly, genes that belong to the protein unfold-
ing response were the only ones that showed a dose
dependent effect with rapamycin, while DR had only a
minor effect on genes belonging to this pathway: among
the 4 genes we studied, only one was altered by DR
(Hspa9). On the other hand, rapamycin altered all of
them, and 3 of them were altered in a dose responsive
fashion. This is relevant because it is known that,
through specific binding to the immunophilin FKBP12,
rapamycin inhibits the activity of mTOR and turns off
protein synthesis (Thomson et al. 2009), which should
result in a reduced stress at the ER level. However, when
we estimated mTOR activity by measuring S6 phosphor-
ylation, we observed a similar degree of mTOR inhib-
ition between rapamycin and DR treatments (Fok et al.,
2013) and thus a similar effect on both protein synthesis
and protein quality control might be expected. As dis-
cussed, there are however significant differences betweenthe effects of DR and rapamycin at the mRNA level
(Figure 4). On the other hand, measurements at the
protein level (Figure 5) indicate that in fact, at this level
the effect of DR on proteostasis pathways is actually
more robust than that observed after rapamycin treat-
ment, with the exception of LC3 (I and II) protein,
where DR and rapamycin have similar effects. Taken to-
gether, the data suggest that in female mice, both DR
and rapamycin achieve the same improvement in protein
quality control, but they appear to do so by different
mechanisms: transcriptional in the case of rapamycin, and
post-transcriptional in the case of DR.
Overall our data indicate that in contrast to the effect
of DR, rapamycin treatment (14 ppm) did not alter gene
expression in any of the chosen pathways in males. On
the other hand, in females the same treatment (14 ppm
rapamycin) did significantly change the expression of
most of the genes studied in a fashion quite similar to
DR. Also, our previous data indicate that even when fed
rapamycin for 21 months, there were no change in
microarray profiles in almost half of the male mice, sug-
gesting that long-term feeding with rapamycin does not
have a strong effect in males, or that the rapamycin’s ef-
fects at the transcriptional level may occur later that 21
months, since we nevertheless observed a difference in
their mean lifespan (Fok et al. 2014b). However, it is
possible that the data obtained from males fed 42 ppm
would look similar to the data from females fed with
rapamycin 14 ppm.
Our data also show that the effects on gene expression
were not dependent on the dose of rapamycin, and this
is in discordance with what has been observed for life-
span (Miller et al., 2014). Similar effects were found in
subcutaneous fat tissue, where the expression of most of
the genes was altered by both DR and rapamycin. How-
ever, in this tissue the effect of rapamycin was more vari-
able and weaker than in liver, as shown by the fact that
from the 9 genes studied, only 3 displayed significant
changes, while 5 genes showed a tendency in the same
direction as DR, but we did not reach statistical signifi-
cance. The remaining gene, Hspa9, showed an increase
with both DR and rapamycin in liver, but surprisingly,
we found that its expression goes down with the higher
concentration of rapamycin (but not DR) in fat. Another
consideration is that higher rapamycin doses may regu-
late different pathways that are not activated by 14 ppm,
and for that reason we do not observed a dose response
effect. This information is not available, but it would be
obtained by a global gene analysis like microarray studies.
Recently Miller et al., 2014, suggested that the gender
difference on the effect of rapamycin might be due to
the fact that females have higher blood levels of rapamy-
cin than males. Although, we observed this difference in
our animals too, with rapamycin blood level being
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observe a significant difference in rapamycin levels in
the liver, the tissue where most of our studies were done
(Additional file 1: Figure S5A and B).
Therefore, based on these results and using a limited
set of genes, we can speculate that in females, rapamycin
has an effect that resembles the expectations for a DR
mimetic more closely than in males, and this may ex-
plain in part why female mice respond better to rapamy-
cin than male. Nevertheless, a deeper analysis must be
done to understand the exact role played by each of
these pathway(s) on the longevity effect mediated by
rapamycin.Additional file
Additional file 1: Dose effect of rapamycin in gene expression
(Figure S1, S2, S4), and protein levels (Figure S3) in the liver and
subcutaneous fat of female mice. All data was obtained from 8 female
mice per group and expressed as mean ±SEM. An asterisk denotes those
values that are significantly different (p ≤ 0.05) from AL mice. Open bar:
AL; Solid bars: DR; Gray bars: Rapa 14 ppm, and striped bars represent
different doses of rapamycin. Figure S1. Dose effect of rapamycin in the
expression of Foxo-1, Sirtuins genes (A), as well genes that belong to
circadian rhythm (B) and proteolytic pathways (C, D) in the liver of female
mice. Figure S2. Dose response in the expression of Lamp 2 (A) and ER
stress pathway (B) in the liver of female mice. Figure S3. Effect of
different doses of rapamycin on protein levels in female liver. Figure S4.
Effect of different doses of rapamycin on gene expression in subcutaneous
fat from females. Figure S5. Intra-hepatic levels of rapamycin are similar
between males and females. Rapamycin levels were measured in blood (A),
and in liver tissue, expressed either as pg/mg of tissue (B), or relative to body
weight (C). Open bars: Males; Solid bars: Females. The data was obtained
from 8 female mice per group and expressed as mean ±SEM. Values were
not statistically different (p ≤ 0.05) in any of the comparisons Table S1.
Primers for qRT-PCR analysis. Table S1. list the primers used in the qRT-PCR
analysis. The 5′ primer and the 3′ primer are listed.Competing interests
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